Navigation Links
While Some New Agents Will Achieve Strong Sales, the Migraine Drug Market Will Decline $1.3 Billion by 2018 as Generic Erosion Takes Toll on Top-Selling Brands
Date:8/5/2009

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although sales of emerging therapies will partially offset losses to generic competitors, the migraine drug market will decline from $4.7 billion in 2008 to $3.4 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Migraine finds that generic erosion of top-selling triptans such as GlaxoSmithKline's Imitrex/Imigran, prescribed for the acute treatment of migraine attacks, and Ortho-McNeil/Janssen-Cilag's anti-epileptic drug Topamax, used for migraine prophylaxis, will constrain the overall migraine market during the next decade and will exert increasing pressure on new products. However, the emergence of Merck's first-in-class calcitonin gene-related peptide receptor antagonist telcagepant as an alternative to triptan therapy will help counteract market losses -- according to the report, telcagepant will garner sales of $1.3 billion in 2018 in the world's major markets.

"Despite a delay in regulatory filing, we forecast that telcagepant will launch for the acute treatment of migraine in 2011 and will achieve blockbuster status, thanks to the drug's triptan-level efficacy, lack of cardiovascular risks, novel mechanism of action and strong marketing support," said Decision Resources Senior Analyst Jonathan Searles. "If the long-term safety of the drug is confirmed, telcagepant will offer a useful alternative for patients in whom the triptans are contraindicated as well as some patients who are refractory to, dissatisfied with or intolerant of triptan treatment. Moreover, we expect that some clinicians, including those who may still avoid triptans because of lingering safety concerns, will adopt telcagepa
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FRC: Ryan Bill Increases Abortion While Claiming to Reduce Need for Abortion
2. While Health Clubs Say No to Canckles, Leading Podiatrists Say No to Toenail Fungus
3. NEUTROGENA(R) and BabyCenter Sun Survey Finds While Mom Knows Best She Can Learn Even More When it Comes to Sun Protection
4. Obesity While Young Boosts Pancreatic Cancer Risk
5. ICM Controls' Award-Winning Comfort Control Center Improves Comfort and Indoor Air Quality While Lowering Energy Costs
6. Almost Half of Those Over 60 Die While Waiting for Kidney Transplant
7. No Matter the Vehicle, Sending Text Messages While Driving Increases Risk of Accidents, Warns New York Auto Accident Lawyer
8. Language Technologies Introduces ReadSmart Edition Apps(TM) for the iPhone(TM) and iPod(R) Touch; Unique Apps Improve Ergonomics of Reading while Retaining Look and Design of Print Books
9. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
10. New Online Home Health Service Launched in California to Expand Direct Patient Care Time While Lowering Costs
11. While the Dangers of Sun Exposure are Widely Understood Americans Fall Short of Adequately Protecting Themselves from the Sun
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... a new study done from the heights of Mount ... increases if you ascend to great heights. They ... high blood pressure was ineffective once climbers reached above ... 27 in the European Heart Journal , could ... level who have sleep apnea, in which a blocked ...
(Date:8/27/2014)... 2014 BESLER Consulting , a ... for hospitals, is pleased to announce that it has ... America’s Fastest-Growing Companies. The list represents the most comprehensive ... entrepreneurs. , "It's been an exciting year for ... in this year's Inc. 5000 list,” said Jonathan Besler, ...
(Date:8/27/2014)... The American Brain Tumor Association ... Basic Research Fellowships and 2014-2015 Discovery Grant Awards. Through ... seeding the field with talented, bright young investigators who ... causes, effects, diagnosis and treatment of brain tumors. This ... on the potential to advance the understanding and treatment ...
(Date:8/27/2014)... drug designed to help regulate the blood,s iron supply shows ... according to results from the first human study ... , the Journal of the American Society of ... red blood cells are in short supply or do not ... not get enough oxygen, since there are fewer red blood ...
(Date:8/27/2014)... A new analysis of clinical trial participation in the ... has found participants are not representative of the larger ... College Hospital cardiologist Dr. Jay Udell. The study authors ... to the wider population, and suggest the use of ... trial participation. , "We know that clinical trials can ...
Breaking Medicine News(10 mins):Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Drug represents first potential treatment for common anemia 2Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2
... a combination of treatments tailor-made to their specific needs to ... immune response to cancer vaccines, because like the rest of ... efficient as we get older. Dr. Joseph Lustgarten, from the ... effects of aging on the immune system and strategies used ...
... are justified, say hearing loss experts who urge prevention , ... typically long -- and get longer when their children become ... about hearing loss. , Parents, in fact, worry more about ... health-related issues, including ear infections, sleep problems and asthma, according ...
... Greater Surface Disinfection to Combat Bad Hygiene , ARLINGTON, Va., ... standing in the lunch line? Or sneeze loudly into the ... (96 percent) have seen you do things like this -- and ... , Even with heightened concerns during this year,s flu season, ...
... , ... on the forefront of adopting social media outlets for physician recruitment , ... Alpharetta, GA (Vocus) October 8, 2009 -- "Jackson ... aspects of physician recruitment and other company functions," says company president, Sandra Garrett., , , ...
... ... malignancy after using a new treatment offered by NeoPlas Innovation. , ... Nashville, Tenn. (PRWEB) October 7, 2009 -- A patient ... after using a new treatment offered by NeoPlas Innovation . All evidence of disease ...
... Bipartisan Policy Center,s Health Care Report Urge Joint Leadership on ... is a statement released by Bipartisan Policy Center Founders and ... Bob Dole: , "After 14 months of work, on June ... It was the culmination of months of work as advisors ...
Cached Medicine News:Health News:Elderly immune system needs a boost 2Health News:As Teens Plug In, Parents Fret 2Health News:As Teens Plug In, Parents Fret 3Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 3Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 2Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 3Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 4Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 5Health News:Inoperable Colon Cancer Resolved After Four Months of New Treatment 2Health News:Inoperable Colon Cancer Resolved After Four Months of New Treatment 3
(Date:8/27/2014)... Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... of pharmaceutical development, clinical trial manufacturing, and advanced analytical ... that it will participate at the upcoming Rodman & ... be held in New York . ... on September 9, 2014 at the New York Palace ...
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... DIEGO , Aug. 27, 2014 Ambit Biosciences (Nasdaq: ... and development of drugs targeting unmet needs in oncology, autoimmune ... Baird 2014 Health Care Conference to be held at The ... on September 3-4, 2014. Alan ... Company and its lead drug candidate, quizartinib, at 1:10 p.m. ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Ambit Announces Participation At Baird 2014 Health Care Conference 2
... Oramed Pharmaceuticals, Inc.,(OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... to present at the 8th National Life,Science & Technology ... by Mr. Nadav Kidron, President and CEO of Oramed,on ... p.m. (local time),at the David Intercontinental Hotel in Tel-Aviv, ...
... Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite ... , COPENHAGEN, June 9 A new analysis ... moderately to severely active rheumatoid arthritis (RA) who ... agents and received subcutaneous injections of SIMPONI(TM) (golimumab) ...
Cached Medicine Technology:Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: